Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Director/PDMR Shareholding

16 Sep 2005 13:06

ReNeuron Group plc16 September 2005 NOTIFICATION OF TRANSACTIONS OF DIRECTORS/PERSONS DISCHARGINGMANAGERIAL RESPONSIBILITY AND CONNECTED PERSONS This form is intended for use by an issuer to make a RIS notification requiredby DR 3.1.4R(1). (1) An issuer making a notification in respect of a transactionrelating to the shares or debentures of the issuer should complete boxes 1 to16, 23 and 24. (2) An issuer making a notification in respect of a derivative relatingto the shares of the issuer should complete boxes 1 to 4, 6, 8,13, 14, 16, 23and 24. (3) An issuer making a notification in respect of options granted to adirector/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. (4) An issuer making a notification in respect of a financialinstrument relating to the shares of the issuer (other than a debenture) shouldcomplete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. Please complete all relevant boxes in block capital letters. 1. Name of the issuer 2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or RENEURON GROUP PLC (ii) DR3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii) (ii) 3. Name of person discharging managerial 4. State whether notification relates to a person responsibilities/director connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person JOHN SINDEN MICHAEL HUNT 5. Indicate whether the notification is in 6. Description of shares (including class), respect of a holding of the person referred debentures or derivatives or financial to in 3 or 4 above or in respect of a instruments relating to shares non-beneficial interest3 7. Name of registered shareholders(s) and, if 8. State the nature of the transaction more than one, the number of shares held by each of them 9. Number of shares, debentures or financial 10. Percentage of issued class acquired (treasury instruments relating to shares acquired shares of that class should not be taken into account when calculating percentage) 11. Number of shares, debentures or financial 12. Percentage of issued class disposed (treasury instruments relating to shares disposed shares of that class should not be taken into account when calculating percentage) 13. Price per share or value of transaction 14. Date and place of transaction 15. Total holding following notification and 16. Date issuer informed of transaction total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage) If a person discharging managerial responsibilities has been granted options bythe issuer complete the following boxes 17. Date of grant 18. Period during which or date on which it can be exercised ANY TIME DURING THE PERIOD ENDING 23 JULY 2014 6 SEPTEMBER 2005 19. Total amount paid (if any) for grant of the 20. Description of shares or debentures involved option (class and number) JOHN SINDEN 650,000 ORDINARY SHARES NIL MICHAEL HUNT 900,000 ORDINARY SHARES 21. Exercise price (if fixed at time of grant) 22. Total number of shares or debentures over or indication that price is to be fixed at the time which options held following notification of exercise £0.10 PER SHARE JOHN SINDEN 1,955,260 OPTIONS AND WARRANTS MICHAEL HUNT 1,929,500 OPTIONS AND WARRANTS 23. Any additional information 24. Name of contact and telephone number for queries TIM MICKLEY, COLLINS STEWART 020 7523 8000 REPLACEMENT OPTIONS GRANTED UNDER THE COMPANY'S NEW SHARE OPTION SCHEME MICHAEL HUNT RENEURON 01483 302 560 Name and signature of duly authorised officer of issuer responsible for making notification MICHAEL HUNT CHIEF EXECUTIVE OFFICER-______________________________________ Date of notification 16/9/05 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Feb 20219:55 amRNSTotal Voting Rights
15th Jan 20212:06 pmRNSSecond Price Monitoring Extn
15th Jan 20212:01 pmRNSPrice Monitoring Extension
15th Jan 20217:00 amRNSClinical Update
6th Jan 20217:00 amRNSAnalyst Conference Call
18th Dec 20204:36 pmRNSPrice Monitoring Extension
18th Dec 20207:00 amRNSNotification of Major Holdings
17th Dec 202012:44 pmRNSNotification of Major Holdings
17th Dec 20207:00 amRNSNotification of Major Holdings
17th Dec 20207:00 amRNSNotification of Allowance granted for US Patent
16th Dec 20205:37 pmRNSNotification of Major Holdings
16th Dec 20202:17 pmRNSNotification of Major Holdings
16th Dec 20207:00 amRNSNotification of Major Holdings
11th Dec 202010:33 amRNSResult of General Meeting and Total Voting Rights
11th Dec 20207:00 amRNSResult of Open Offer
25th Nov 20204:41 pmRNSSecond Price Monitoring Extn
25th Nov 20204:36 pmRNSPrice Monitoring Extension
25th Nov 20202:06 pmRNSSecond Price Monitoring Extn
25th Nov 20202:00 pmRNSPrice Monitoring Extension
25th Nov 202011:05 amRNSSecond Price Monitoring Extn
25th Nov 202011:00 amRNSPrice Monitoring Extension
24th Nov 20204:41 pmRNSSecond Price Monitoring Extn
24th Nov 20204:36 pmRNSPrice Monitoring Extension
24th Nov 20202:06 pmRNSSecond Price Monitoring Extn
24th Nov 20202:00 pmRNSPrice Monitoring Extension
24th Nov 20207:15 amRNSResult of Placing and Subscription and GM Notice
24th Nov 20207:00 amRNSInterim Results
23rd Nov 20205:42 pmRNSProposed Placing, Subscription and Open Offer
2nd Nov 20207:00 amRNSTotal Voting Rights
10th Sep 20203:59 pmRNSResult of AGM
10th Sep 20207:00 amRNSAGM Trading Update
1st Sep 20207:00 amRNSBlock Listing Review and Total Voting Rights
18th Aug 20207:00 amRNSPosting of Annual Report and Notice of AGM
12th Aug 20207:00 amRNSChanges to Non-Executive Board
3rd Aug 20207:00 amRNSTotal Voting Rights
31st Jul 20207:00 amRNSNotification of Allowance granted for US Patent
20th Jul 20207:00 amRNSPreliminary Results
14th Jul 20203:06 pmRNSNotification of Major Holdings
29th Jun 20207:00 amRNSFurther Positive Data in Retinal Clinical Trial
25th Jun 20207:00 amRNSNew Exosome Research Collaboration
17th Jun 20207:00 amRNSRegulatory Approvals and Programme Update
7th May 20207:00 amRNSCTX cell line shows further potential
7th Apr 20202:06 pmRNSSecond Price Monitoring Extn
7th Apr 20202:00 pmRNSPrice Monitoring Extension
7th Apr 202011:06 amRNSSecond Price Monitoring Extn
7th Apr 202011:00 amRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSExosome Research Collaboration
3rd Apr 20207:00 amRNSCOVID-19 Update
16th Mar 20204:43 pmRNSSecond Price Monitoring Extn
16th Mar 20204:39 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.